NASDAQ:SUPN Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis $29.72 +0.52 (+1.78%) As of 11/13/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Supernus Pharmaceuticals Stock (NASDAQ:SUPN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SUPN alerts:Sign Up Key Stats Today's Range$28.81▼$29.9250-Day Range$26.16▼$44.6052-Week Range$25.92▼$42.81Volume2.07 million shsAverage Volume3.81 million shsMarket Capitalization$3.51 billionP/E Ratio8.30Dividend YieldN/APrice Target$60.20Consensus RatingModerate Buy Company Overview Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease. Founded in 2005 and headquartered in Rockville, Maryland, Supernus expanded its commercial portfolio through acquisitions, including its 2022 acquisition of Adamas Pharmaceuticals. The company is led by President and Chief Executive Officer Jack Khattar and primarily serves the U.S. market.AI Generated. May Contain Errors. Read More Supernus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreSUPN MarketRank™: 4.2267296836 of 5 starsSupernus Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 65th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialSupernus Pharmaceuticals has a consensus price target of $60.20, representing about 102.6% upside from its current price of $29.72.Amount of Analyst CoverageSupernus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Supernus Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-0.53% Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to decrease by -0.53% in the coming year, from $3.80 to $3.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is 8.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is 8.30, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.Price to Earnings Growth RatioSupernus Pharmaceuticals has a PEG Ratio of 0.59. PEG Ratios below 1 indicate that a company could be undervalued. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.94% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 3.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 14.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.57 News SentimentSupernus Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Supernus Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest10 people have searched for SUPN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders8.50% of the stock of Supernus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsSupernus Pharmaceuticals has minimal institutional ownership at this time.Read more about Supernus Pharmaceuticals' insider trading history. Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SUPN Stock News HeadlinesBank of America Initiates Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)November 11 at 1:43 AM | americanbankingnews.comSupernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run ContinuesNovember 10, 2026 | finance.yahoo.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount. | Base Camp Trading (Ad)Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in LondonNovember 10, 2026 | globenewswire.comSupernus undervalued after Indivior merger, says Bank of AmericaNovember 9, 2026 | ca.finance.yahoo.comThis Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayNovember 9, 2026 | benzinga.comCantor Fitzgerald Forecasts Strong Price Appreciation for Supernus Pharmaceuticals (NASDAQ:SUPN) StockNovember 6, 2026 | americanbankingnews.comSupernus, Inc.(NasdaqGS:SUPN) added to NASDAQ Composite IndexNovember 5, 2026 | marketscreener.comMSee More Headlines SUPN Stock Analysis - Frequently Asked Questions How have SUPN shares performed this year? Supernus Pharmaceuticals' stock was trading at $49.70 at the start of the year. Since then, SUPN shares have decreased by 40.2% and is now trading at $29.72. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its quarterly earnings results on Thursday, October, 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by $0.14. Supernus Pharmaceuticals's revenue for the quarter was up 18.0% on a year-over-year basis. Read the conference call transcript. When did Supernus Pharmaceuticals IPO? Supernus Pharmaceuticals (SUPN) raised $75 million in an initial public offering on Tuesday, May 1st 2012. The company issued 5,769,000 shares at a price of $12.00-$14.00 per share. Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' top institutional investors include State Street Corp (2.18%), Stephens Investment Management Group LLC (1.39%), GW&K Investment Management LLC (1.16%) and Pictet Asset Management Holding SA (0.75%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola, Jonathan Rubin, Timothy C Dec and Bethany Sensenig. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Block (XYZ), Netflix (NFLX) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings10/29/2026Record date for 11/6 Dividend10/30/2026Dividend Payable11/06/2026Today11/14/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SUPN's financial health is in the Red zone, according to TradeSmith. SUPN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SUPN CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees827Year Founded2005Price Target and Rating Average Price Target for Supernus Pharmaceuticals$60.20 High Price Target$87.00 Low Price Target$47.00 Potential Upside/Downside+102.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$3.58 Trailing P/E Ratio8.30 Forward P/E Ratio7.86 P/E Growth0.59Net Income$210 million Net Margins32.75% Pretax Margin39.16% Return on Equity-418.04% Return on Assets42.96% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.50 Sales & Book Value Annual Sales$1.24 billion Price / Sales2.83 Cash Flow$2.77 per share Price / Cash Flow10.74 Book Value($0.51) per share Price / Book-58.27Miscellaneous Outstanding Shares118,040,000Free Float108,002,000Market Cap$3.51 billion OptionableOptionable Beta0.84 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:SUPN) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
